Perrigo Company plc
IEFinancials
Valuation Metrics
Perrigo Company plc's Market Cap is $1.48B. At end of 2025 it was $1.89B. Ranked #2254 of 3,112 in US market (top 72%), #1355 of 1,667 on NYSE (top 81%), #167 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.48B | US#2,254/3,112 Sec#167/269 |
| Revenue | $4.18B | US#1,009/3,112 Sec#30/269 |
| Net Income | $-1.82B | US—/3,112 Sec—/269 |
| Total Assets | $7.98B | US#1,112/3,112 Sec#32/269 |
| Net Assets | $2.50B | US#1,104/3,112 Sec#37/269 |
| Employees | 8,100 | US#663/3,112 Sec#17/269 |
| Value | ||
| P/B | 0.59x | US#95/3,112 Sec#2/269 |
| P/S | 0.35x | US#178/3,112 Sec#2/269 |
| FCF Yield | 7.29% | US#826/3,112 Sec#30/269 |
| Profitability | ||
| ROE | -72.74% | US#2,813/3,112 Sec#205/269 |
| ROA | -22.77% | US#2,805/3,112 Sec#134/269 |
| Op. Margin | 5.67% | US#2,002/3,112 Sec#75/269 |
| Revenue Growth | -7.16% | US#2,589/3,112 Sec#141/269 |
| Financial Health | ||
| Debt Ratio | 219.49% | US#1,878/3,112 Sec#206/269 |
| Total Debt | $3.81B | US#800/3,112 Sec#26/269 |
| FCF | $108M | US#1,638/3,112 Sec#60/269 |
| Cash | $357M | US#1,303/3,112 Sec#70/269 |
| Current Ratio | 2.72x | US#908/3,112 Sec#203/269 |
| Dividend | ||
| Div. Yield | 10.74% | US#64/3,112 Sec#1/269 |
| Div. Growth | 3.63% | US#922/3,112 Sec#14/269 |
| Performance | ||
| 1Y Return | -58.54% | US#3,035/3,112 Sec#257/269 |
| 1M Return | -3.18% | US#2,040/3,112 Sec#105/269 |
| From 52W High | -59.08% | US#2,930/3,112 Sec#240/269 |
| 1Y MDD | -66.32% | US#2,855/3,112 Sec#238/269 |
| Trading | ||
| Volume | 2,611,515 shares | US#708/3,112 Sec#62/269 |
| Trading Value | $28M | US#1,784/3,112 Sec#125/269 |
| Per Share | ||
| EPS | $-10.29 | US—/3,112 Sec—/269 |
| BPS | $21.19 | US#1,147/3,112 Sec#29/269 |
Company Info
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.